Cwm LLC Has $384,000 Holdings in REGENXBIO Inc. $RGNX

Cwm LLC raised its stake in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 75.4% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 46,816 shares of the biotechnology company's stock after buying an additional 20,120 shares during the quarter. Cwm LLC owned 0.09% of REGENXBIO worth $384,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in shares of REGENXBIO by 9.1% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 27,756 shares of the biotechnology company's stock worth $198,000 after buying an additional 2,326 shares during the period. Brooklyn Investment Group increased its position in shares of REGENXBIO by 163.7% during the 1st quarter. Brooklyn Investment Group now owns 5,583 shares of the biotechnology company's stock worth $40,000 after purchasing an additional 3,466 shares in the last quarter. American Century Companies Inc. increased its position in shares of REGENXBIO by 6.9% during the 1st quarter. American Century Companies Inc. now owns 101,579 shares of the biotechnology company's stock worth $726,000 after purchasing an additional 6,553 shares in the last quarter. Pallas Capital Advisors LLC increased its position in REGENXBIO by 67.1% in the 2nd quarter. Pallas Capital Advisors LLC now owns 17,407 shares of the biotechnology company's stock valued at $143,000 after acquiring an additional 6,992 shares in the last quarter. Finally, Corton Capital Inc. increased its position in REGENXBIO by 54.6% in the 1st quarter. Corton Capital Inc. now owns 20,528 shares of the biotechnology company's stock valued at $147,000 after acquiring an additional 7,252 shares in the last quarter. 88.08% of the stock is owned by institutional investors.

REGENXBIO Stock Up 3.6%

Shares of RGNX opened at $13.03 on Friday. REGENXBIO Inc. has a 12-month low of $5.03 and a 12-month high of $13.39. The business's fifty day moving average is $10.06 and its 200 day moving average is $9.06. The stock has a market cap of $658.15 million, a P/E ratio of -3.79 and a beta of 1.17.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its earnings results on Thursday, August 7th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.13) by ($0.25). REGENXBIO had a negative return on equity of 66.95% and a negative net margin of 112.70%.The firm had revenue of $21.36 million during the quarter, compared to the consensus estimate of $40.87 million. On average, analysts expect that REGENXBIO Inc. will post -4.84 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Barclays reduced their price objective on shares of REGENXBIO from $50.00 to $37.00 and set an "overweight" rating on the stock in a research note on Friday, August 8th. Wall Street Zen downgraded shares of REGENXBIO from a "hold" rating to a "strong sell" rating in a report on Saturday, August 9th. Weiss Ratings reiterated a "sell (d-)" rating on shares of REGENXBIO in a report on Saturday. Royal Bank Of Canada cut their price objective on shares of REGENXBIO from $21.00 to $17.00 and set an "outperform" rating for the company in a research report on Friday, August 8th. Finally, HC Wainwright reissued a "buy" rating and issued a $34.00 target price on shares of REGENXBIO in a report on Tuesday, October 7th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, REGENXBIO presently has an average rating of "Moderate Buy" and an average price target of $28.38.

Insider Activity at REGENXBIO

In other news, CEO Curran Simpson sold 20,811 shares of REGENXBIO stock in a transaction on Thursday, October 9th. The stock was sold at an average price of $12.62, for a total transaction of $262,634.82. Following the sale, the chief executive officer directly owned 216,162 shares in the company, valued at $2,727,964.44. The trade was a 8.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last quarter, insiders sold 36,169 shares of company stock worth $416,598. Insiders own 12.79% of the company's stock.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.

Want to see what other hedge funds are holding RGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for REGENXBIO Inc. (NASDAQ:RGNX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.